arrow
M

Mark Fitzgerald

berry consultants llc
H指数:25
被引数:7,254

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
2024-10-010
OAAI
Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials
2023-11-1423
OA
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19 A Randomized Clinical Trial

血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂对新型冠状病毒肺炎住院患者无器官支持天数的影响随机临床试验

2023-04-1135
OA
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial
2023-01-0379
OA
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
LANCET
IF88.5
2023-01-01237
OAAI
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial
2022-04-0590
OA
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
2022-03-2328
OAAI
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial

恢复期血浆对重症新型冠状病毒肺炎患者无器官支持天数的影响: 一项随机临床试验

2021-11-02148
OA
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
2021-09-0155
OAAI
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
LANCET
IF88.5
2021-09-01157
OAAI
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
LANCET
IF88.5
2021-03-01190
OAAI